Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Capital Expenditures (2016 - 2025)

IGC Pharma (IGC) has disclosed Capital Expenditures for 15 consecutive years, with $29000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures changed 0.0% to $29000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $82000.0, a 45.33% decrease, with the full-year FY2025 number at $112000.0, down 18.84% from a year prior.
  • Capital Expenditures was $29000.0 for Q3 2025 at IGC Pharma, up from $8000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $582000.0 in Q4 2022 to a low of -$404000.0 in Q3 2022.
  • A 5-year average of $48526.3 and a median of $29000.0 in 2024 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 2055.56% in 2022; the steepest drop was 1362.5% in 2022.
  • IGC Pharma's Capital Expenditures stood at $27000.0 in 2021, then skyrocketed by 2055.56% to $582000.0 in 2022, then tumbled by 88.32% to $68000.0 in 2023, then crashed by 60.29% to $27000.0 in 2024, then rose by 7.41% to $29000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Capital Expenditures are $29000.0 (Q3 2025), $8000.0 (Q2 2025), and $18000.0 (Q1 2025).